• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    Adare Pharma Solutions

    Quotient Sciences

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Adare Pharma Solutions

    Alcami

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    Bio-Outsourcing On the Rise

    Fewer companies go 100% in-house

    Related CONTENT
    • Ascendia Pharmaceuticals Poised for Expansion
    • Moderna, Catalent Enter Long-Term Strategic Vax Pact
    • PharmParts – This Makes Sense!
    • CordenPharma Enters Alliance with Nanos of South Korea
    • The Ever-Evolving World of Combination Products
    Eric S. Langer09.07.11

    For the first time since 2008, the number of biotherapeutic developers manufacturing 100% in-house has dropped in each production system surveyed. According to data released in BioPlan Associates' 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1 for the first time since we began measuring outsourcing, more than half of respondents using mammalian cell culture or microbial fermentation systems report that they are now outsourcing at least some of their manufacturing.1


    Our annual study provides indicators of global outsourcing activities, and points to the increasing use of CMOs to control costs and manage internal staff and resources. Among many areas of coverage, this year’s survey asked respondents the percentage of production currently outsourced by manufacturing method — mammalian, microbial, yeast, plant, and insect — and compared the data to previous years. The results, which include responses from 352 global biomanufacturers, show that biologics developers recognize that, as their production capacity constraints shift, bio-CMOs can provide the necessary technical expertise and flex capacity to reduce risks associated with building internal capacity. 
     


    Biopharma CMOs are expanding their manufacturing competence through the use of novel technologies, single-use/disposable bioreactors and other differentiated bioprocessing services. Expansions are resulting in increased adaptability, lower costs, faster turnaround and higher yields. For clients, this means that more CMOs are likely to meet their needs (more competition leads to more choice). In addition, the costs for using CMOs for product manufacturing are holding steady, even as service offerings improve. This year’s study shows CMO pricing to remain virtually flat, with only bulk formulating increasing around an average of 2%. Most of the other 10 CMO areas tested will remain below a 1% price increase this year. 


    Outsourcing Results


    This year, among respondents producing in mammalian cell culture, 45% indicated they performed all their production “in-house” (down from last year’s 57%). In addition, 17.6% of respondents outsourced less than 10% of their production, and 16.2% outsourced from 10% to 25%. Over the past few years, the percentage of biotherapeutic developers who are doing all of their mammalian cell production “in-house” shifted down slightly from 55.6% in 2006 to 57% in 2010, and to 45% today. 


    For microbial fermentation, 43.8% of this year’s respondents indicated they performed all their production “in-house,” vs. 64.2% last year, while 8.3% of respondents outsourced 90-100% of their production. The percentage of biotherapeutic developers who were doing all their microbial fermentation “in-house” has increased slightly over the past five years (between 58.1% in 2005 vs. 64.2% last year, and 43.8% this year). 
     


    Interestingly, in comparison with other manufacturing platforms, insect cell culture was reported to be done 65% in-house, (followed by 59.1% doing yeast culture in-house). With few insect and plant cell production platforms being used for commercial manufacture, this indicates that these systems are primarily being used for in-house manufacture of preclinical and perhaps some early clinical supplies. The overall trend toward using more outsourcing is paralleled by the fact that more “platform processes” are becoming available, a fact that supports outsourcing.


    Key Findings 


    • Mammalian cell systems: 45% (vs. 57% last year, and 53% the previous year) of respondents indicated that they outsourced no production.

    • Microbial: 43.8% (vs. 64.2% last year, and 60% in 2009) outsourced no production.

    • Yeast: 59.1% (vs. 60.7% last year, and 69% in 2009) outsourced no production.

    • Plant cells: 58% outsourced no production (compared with 75% last year).

    • Insect cells: 65% outsourced no production. 


    Looking Ahead: Five-Year Projections For Outsourcing Activities


    Respondents also estimated the overall percentage of their production that they expected to outsource by 2015. The trend our study shows towards greater outsourcing in all manufacturing platforms is supported by data concerning future projections. Indeed, this year, 63.5% of respondents projected that at least some production in mammalian cell culture will be outsourced within five years, compared with 63.1% last year (and 53.5% the previous year).
    The fact that mammalian systems manufacturers have not significantly changed their five-year projection this year suggests a relatively stable production environment. For microbial fermentation, 59.6% of respondents this year indicated that at least some of their fermentation will be outsourced within five years. In comparison, 52.7% last year and 43.9% in 2009 indicated they would outsource at least some microbial production. Additionally, companies expecting to outsource at least some insect cell production expanded significantly to 44.4% this year, up from only 16.7% in 2010. Data regarding outsourcing of yeast, plant and insect cell production show greater year-on-year variability due to the relatively smaller percentage of facilities operating in these systems. 


    Trends in Outsourcing Activities


    Outsourcing today continues to be dominated by relatively lower value-added services, such as fill/finish and product testing. To dig deeper into outsourcing trends, and to determine where the greatest changes are likely to occur, we examined 23 current outsourcing activities and asked respondents which areas they will be outsourcing more often over the next 24 months.

    We discovered that the primary outsourced activity today is product characterization testing, with over 70% of biopharmaceutical companies outsourcing at least some of this activity. Validation services (69.3%) and plant maintenance services (67.1%) follow closely. At the other end of the scale, there appears to be relatively low outsourcing activity for design of experiments, downstream and upstream process development, and QbD initiatives. 


    One activity that showed a significant increase in outsourcing from last year was API biologics manufacturing, which jumped to 44.3% of respondents who are now outsourcing at least some of this activity (compared to 29.3% in 2010). This increase is reflected in the growth of companies such as Albany Molecular Research, Inc. (AMRI), whose president and chief executive officer, Thomas E. D'Ambra, attributed its strong second quarter results to “continued strength in development and large scale API manufacturing operations as both biotech and pharmaceutical companies maintain focus on their late-stage portfolios.”2


    API outsourcing for biologics has been around for decades, with Lonza in the UK and Boehringer Ingelheim leading in mammalian and microbial systems, respectively. Today, we are seeing an expansion of CMOs and biosimilar manufacturers (see www.top1000bio.com) globally due to the emergence of facilities in India, China, Korea, Malaysia and elsewhere. These facilities are emerging to support both domestic production, and to gain a foothold in the developing opportunities for biologics production. In addition, despite the current stable capacity worldwide for biological manufacturing, drug innovator companies continue to offer their excess or idle capacity as CMO operations. 


    Outsourcing Growth Trends


    We evaluated outsourcing trends by asking respondents where they believed they would be outsourcing significantly more projects over the next 24 months. Of the 24 activities tested, three stood out as areas where substantial changes will occur during the next two years. We found that 23% of biomanufacturers will be outsourcing significantly more ‘Fill/finish operations’ compared with their current levels. Although this figure is slightly down from 2010 (25%), there appears to be a trend towards more outsourcing of this activity in the future, as more and more “high-end” fill/finish operations are used, such as prefilled syringes, cartridge systems and multi-use adjustable syringes. 
     


    Following fill/finish operations is ‘validation services,’ noted by 22.1% as being a big gainer over the next 24 months. Validation services result from a lack of internal staff with the ‘brain-power’ and ‘hands-on’ capacity to provide the corresponding know-how when it comes to late stage process / methods validation in a company that wants to rapidly move from early-stage clinic into late stage and commercial. Highly specialized providers of validation services have been active for many years and their businesses continue to prosper. 


    Following ‘validation services’ as a future outsourcing activity was ‘downstream production operations,’ which was noted by 22.0% of respondents this year (compared to 14.3% in 2010). According to Dr. Wolfgang Noe, senior consultant at BioProcess Technology Consultants, this may be due to the fact that “more companies tend to outsource the ‘standard, platform’ processes, while focusing internally around the more challenging molecules.”1


    While the world economy continues to take a battering, biopharmaceuticals and related industry segments remain growth areas. Even so, the biopharma industry is becoming rapidly globalized — according to our recently released Top 1000 Global Biopharmaceutical Manufacturing Index™,3 although the U.S. has the largest concentration of global biomanufacturing capacity (not just number of facilities), at 37.5%, China (8.5%), India (8.0%), and Japan & other Asian countries (9.2%) are growing rapidly. 


    Given this increasingly competitive global environment, the biopharma industry continues to focus on productivity, efficiency, getting more out of existing internal resources, and maximizing performance from provider relationships. Outsourcing plays a role in this equation as companies recognize the strategic necessity of using internal resources more efficiently, while outsourcing activities outside their core competencies. This outsourcing of processes, while enabling a focus on a company’s skill base, also yields economic benefits. Even so, as CMOs offer expertise, tools and capacity that biopharma companies don’t have in-house — or that they elect to outsource as part of their strategic planning — it will increasingly become less about direct cost savings, and more about doing things better and more competitively.


    Although outsourcing can improve overall efficiency and reduce costs, the management of relationships continues to be challenging, and necessitates flexibility to meet clients’ shifting needs. The rise of outsourcing has resulted in many companies establishing centralized contracting groups to handle the complex and time-consuming business of selecting and managing partners. Our study indicates that this growth is also resulting in ongoing and, in many cases, unresolved problems associated with managing relationships, partners and projects. These problems are likely to continue to expand along with current outsourcing trends. As the use of outsourcing partners becomes more embedded into company strategy, effective management, including the establishment and maintenance of strong working relationships will become more critical. Addressing these managerial, communications, and partnering problems may become a bottleneck that determines just how quickly and successfully the outsourcing industry grows. 

     

    References

    1 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates, April 2011, 490 pages.

    2 AMRI Announces Second Quarter Results. 8 August, 2011. http://www.marketwatch.com/story/amri-announces-second-quarter-2011-results-2011-08-08?reflink=MW_news_stmp

    3 BioPlan’s Top 1000 Global Biopharmaceutical Facilities Index™, www.top1000bio.com, accessed August 25, 2011

     

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a Rockville, MD-based biotechnology and life sciences marketing research and publishing firm established in 1989. He can be reached at elanger@bioplanassociates.com or 301-921-5979.

     

    Survey Methodology: The 2011 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production in the series of annual evaluations by BioPlan Associates, Inc. yields a composite view and trend analysis from 352 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) in 31 countries. The methodology also encompassed an additional 186 direct suppliers of materials, services and equipment to this industry. This year's survey covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in downstream purification, quality management and control, hiring issues, and employment. The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in the world's major markets in the U.S. and Europe.

    Related Searches
    • biopharma companies
    • contract manufacturing organizations
    • biopharmaceutical companies
    • CMO
    Suggested For You
    Ascendia Pharmaceuticals Poised for Expansion Ascendia Pharmaceuticals Poised for Expansion
    Moderna, Catalent Enter Long-Term Strategic Vax Pact Moderna, Catalent Enter Long-Term Strategic Vax Pact
    PharmParts – This Makes Sense! PharmParts – This Makes Sense!
    CordenPharma Enters Alliance with Nanos of South Korea CordenPharma Enters Alliance with Nanos of South Korea
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    SK Capital Completes Acquisition of BFS from Catalent Pharma Solutions SK Capital Completes Acquisition of BFS from Catalent Pharma Solutions
    Steriline Delivers New Manufacturing Line to Bess Pro Steriline Delivers New Manufacturing Line to Bess Pro
    Vibalogics Updates U.S. Leadership Team Vibalogics Updates U.S. Leadership Team
    CureVac, Celonic Enter COVID-19 Vax Mfg. Pact CureVac, Celonic Enter COVID-19 Vax Mfg. Pact
    Advanced Analytics Advancing Development of Genetic Vaccines Advanced Analytics Advancing Development of Genetic Vaccines
    Chime Biologics Expands CDMO Capabilities Chime Biologics Expands CDMO Capabilities
    Jubilant, Novavax Enter COVID-19 Vaccine Partnership Jubilant, Novavax Enter COVID-19 Vaccine Partnership
    Aenova Expands Sterile Production Capacity Aenova Expands Sterile Production Capacity
    EMA Approves BioNTech EMA Approves BioNTech's COVID Vax Production at Marburg Site
    Asymchem Expands Oligonucleotides Mfg. Capacity Asymchem Expands Oligonucleotides Mfg. Capacity

    Related Bio News & Views

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development

      CMOs Demanding More Innovations

      Chromatography and single-use equipment top list
      Eric Langer , BioPlan Associates 11.13.13

    • Biologics, Proteins, Vaccines | Capsules | Clinical Trial Materials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Parenterals | Process Development | QA/QC | Validation

      How Far Do You Go?

      ...
      Victor A Vinci, Ph.D., Cook Pharmica 06.05.13

    • Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Scale-up/Technology Transfer
      Future Bio-Capacity Constraints

      Future Bio-Capacity Constraints

      Top 10 factors from a new survey
      Eric S. Langer, BioPlan Associates, Inc. 09.06.12


    • Analytical Services | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Capsules | Cleaning Validation | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Process Development | Process Validation | Regulatory Affairs | Scale-up/Technology Transfer | Toxicology | Validation

      The FDA Says You Are Responsible

      . . . But do you know who you are?
      E. Morrey Atkinson, Ph.D., Cook Pharmica 05.04.12

    • Bio News | Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development
      Industry Adopting More Complex Devices

      Industry Adopting More Complex Devices

      CMOs are spending twice as much as bio-innovators on single-use devices
      Eric S. Langer, BioPlan Associates, Inc. 03.07.12

    • Biologics, Proteins, Vaccines | Capsules | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | R&D | Scale-up/Technology Transfer

      Whose Platform Is It Anyway?

      Both Sides of the Table
      E. Morrey Atkinson, Ph.D. 01.23.12


    • Biologics, Proteins, Vaccines | Extractables and Leachables | Facilities | GMPs/GCPs | Methods Development | Process Development | Process Validation | QA/QC | Validation

      Why Not Do an Engineering Lot?

      Both Sides of the Table – A discussion of CMO/client perspectives
      E. Morrey Atkinson. Ph.D. 10.11.11

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login